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Introduction
Tumor necrosis factor receptor-1 associated periodic
syndrome (TRAPS) is a periodic fever syndrome, charac-
terized by recurrent fever attacks associated with rashes,
musculoskeletal and abdominal pain, and periorbital
edema. In few patients TNF inhibitors have been shown
to be effective, however, their efficacy tends to decrease
over time [1-4]. Anti-IL-1 treatments have also been used
in an effort to provide long term control of the inflamma-
tory manifestations.
Objectives
The main objective was to determine whether canakinu-
mab (CAN) induced complete or almost complete
response in patients with active TRAPS at Day 15, as
defined by Physician’s Global Assessment (PGA). Evolu-
tion of C-reactive protein (CRP) and serum amyloid A
(SAA), relapse rate and time to remission were additional
measures. An additional objective was to determine the
appropriate dosing for further development of CAN treat-
ment in TRAPS patients.
Patients and methods
This was an open-label, single treatment arm, efficacy and
safety study of monthly CAN 150 mg (2 mg/kg for patient
≤40 kg) SC in patients with active recurrent or chronic
TRAPS [NCT01242813]. Patients were treated for
4-months with a maximum 5-month follow-up period.
The initial follow-up period was followed by a maximum
24-month long-term treatment period. Here we report the
efficacy and safety results of the completed study.
Results
A total of 20 patients were exposed to study medication,
out of which 18 (90%) patients completed the study. At
Day 15, complete response or almost complete response
was achieved in 18 patients [90%; 95% CI: 75.1, 99.9],
while 20 (100%) and 12 (60%) patients had clinical and
serological remission, respectively. Already at Day 8, 16
patients (80%) achieved a complete or almost complete
response, while 18 (90%) and 7 (35%) patients had clini-
cal and serological remission, respectively. A total of
60% of patients experienced study drug-related AEs,
most commonly upper respiratory tract infections.
Seven patients (35%) experienced SAEs, none of which
were related to study drug. Furthermore, there were no
deaths during the study.
Conclusions
Canakinumab was effective in rapidly improving clinical
signs and symptoms of TRAPS, whilst normalizing sero-
logical inflammatory markers and providing sustained
disease control. The safety profile was consistent with
previous canakinumab studies in other indications.
These data support the ongoing development of canaki-
numab in this therapeutic area.
Authors’ details
1University College London, London, UK. 2Pediatric Clinic, University of
Brescia, Brescia, Italy. 3Policlinico S. Matteo, Pavia, Italy. 4Hospital Sciacca,
Sciacca, Italy. 5Novartis Pharma AG, Basel, Switzerland. 6G Gaslini Institute,
Genova, Italy.1University College London, London, UK
Full list of author information is available at the end of the article
Lachmann et al. Pediatric Rheumatology 2015, 13(Suppl 1):O59
http://www.ped-rheum.com/content/13/S1/O59
© 2015 Lachmann et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Published: 28 September 2015
References
1. Simon A, et al : Am.J.Med 2004, 117:208-210.
2. Weyhreter H, et al : J Pediatr 2003, 142:191-193.
3. Jacobelli S, et al : Rheumatology 2007, 46(7):1211-1212.
4. Arostegui JI, et al : Eur.J.Pediatr 2005, 164:13-16.
doi:10.1186/1546-0096-13-S1-O59
Cite this article as: Lachmann et al.: Canakinumab treatment in patients
with active recurrent or chronic TNF-receptor associated syndrome
(TRAPS): Efficacy and safety results from a proof of concept study.
Pediatric Rheumatology 2015 13(Suppl 1):O59.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lachmann et al. Pediatric Rheumatology 2015, 13(Suppl 1):O59
http://www.ped-rheum.com/content/13/S1/O59
Page 2 of 2
